Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience - Report - MDSpire

Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience

  • By

  • Ashley Lu

  • Wei-Ting Chen

  • Maria Dalby

  • Diego Sainz Garcia

  • Marisa Vanheusden

  • Luuk E. de Vries

  • Veerle van Lieshout

  • Araks Martirosyan

  • Katleen Craessaerts

  • Sebastiaan Moonen

  • Magdalena Zielonka

  • Iordana Chrysidou

  • Anke Misbaer

  • Leen Wolfs

  • Benjamin Pavie

  • Dick Swaab

  • Dietmar Rudolf Thal

  • Inge Huitinga

  • Annemieke Rozemuller

  • Susan Karijn Rohde

  • Marc Hulsman

  • Henne Holstege

  • Rita Balice-Gordon

  • Niels Plath

  • Mark Fiers

  • Bart De Strooper

  • June 4, 2026

  • 0 min

Share

Transitions in Human Microglia at the Aβ–tau Intersection Relate to Different Pathways Leading to Dementia and Resilience

Overview

This study investigates the role of microglial transitions at the intersection of Aβ and tau pathology in Alzheimer's disease (AD). Findings suggest that distinct immune responses contribute to cognitive resilience in octogenarians and centenarians, highlighting potential therapeutic targets.

Background

Alzheimer's disease (AD) represents a significant public health challenge, with increasing prevalence globally. Understanding the biological mechanisms that differentiate individuals who develop dementia from those who remain cognitively intact despite advanced pathology is crucial. This study challenges traditional linear models of AD progression by proposing a nonlinear framework that emphasizes the role of microglial responses in cognitive resilience.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Microglial activation and immune pathways are major genetic determinants of AD risk.
  • Octogenarians without dementia exhibited early PIG responses despite Aβ burden.
  • Cognitively intact centenarians displayed late PIG activation while resisting tau accumulation.
  • Resilience in AD may emerge through distinct immune trajectories at the Aβ–tau interface.
  • Spatial transcriptomics can link cellular states to local Aβ and tau pathology.

Clinical Implications

The findings suggest that targeting microglial modulation at the Aβ–tau interface may offer new therapeutic avenues for AD. Understanding individual immune responses could inform personalized treatment strategies for patients with varying cognitive outcomes.

Conclusion

This research underscores the complexity of AD pathology and the importance of immune responses in determining cognitive resilience. Further exploration of microglial roles may enhance therapeutic approaches in Alzheimer's disease.

Related Resources & Content

  1. Acta Neuropathologica, 2014 -- The Role of Microglia in Central Nervous System Disorders Across Development and Aging
  2. Acta Neuropathologica, 2019 -- Exploring the Evolving Genetic Framework of Alzheimer’s Disease: Transitioning from the Amyloid Cascade to the Hypothesis of Genetically Induced Synaptic Dysfunction
  3. Acta Neuropathologica, 2024 -- Analysis of Early Cellular Senescence in Alzheimer’s Disease Through Single Nuclear Transcriptomic Approaches
  4. Acta Neuropathologica, 2014 -- Interactions between Tau Aggregation and Amyloid-β in Alzheimer's Disease
  5. Criteria for Diagnosis and Staging of Alzheimer's Disease | alz.org
  6. Revised criteria for the diagnosis and staging of Alzheimer’s disease - PMC
  7. FDA approves treatment for adults with Alzheimer’s disease | FDA
  8. Revised criteria for the diagnosis and staging of Alzheimer’s disease | Nature Medicine
  9. Donanemab: Appropriate use recommendations - PubMed
  10. Donanemab Appropriate Use Recommendations - PMC
  11. FDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients | Eli Lilly and Company
  12. FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients | GE HealthCare
  13. FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer's Disease
  14. Frontiers | Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease
  15. Risk of amyloid-related imaging abnormalities associated with anticoagulant therapy in patients with Alzheimer’s disease treated with anti-amyloid monoclonal antibodies: a systematic review and meta-analysis | Journal of Neurology, Neurosurgery & Psychiatry
  16. Clinical Practice Guideline: Blood-Based Biomarkers in Specialty Care | Alzheimer's Association®
  17. Neurodegeneration and glial activation related blood biomarkers in Alzheimer's disease: A systematic review and an updated meta- analysis - ScienceDirect

Original Source(s)

Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience

  • by Ashley Lu, Wei-Ting Chen, Maria Dalby, Diego Sainz Garcia, Marisa Vanheusden, Luuk E. de Vries, Veerle van Lieshout, Araks Martirosyan, Katleen Craessaerts, Sebastiaan Moonen, Magdalena Zielonka, Iordana Chrysidou, Anke Misbaer, Leen Wolfs, Benjamin Pavie, Dick Swaab, Dietmar Rudolf Thal, Inge Huitinga, Annemieke Rozemuller, Susan Karijn Rohde, Marc Hulsman, Henne Holstege, Rita Balice-Gordon, Niels Plath, Mark Fiers, Bart De Strooper

  • June 4, 2026

Related Content

Cognitive Trajectories and Subsequent Accelerometer-Measured Movement Behavior in Older Adults

Late-life difficult-to-treat depression and dementia subtypes: a naturalistic cohort study using electronic health records

Stage-stratified benefits of AI-radiomics PET in early Alzheimer’s disease: a systematic review and meta-analysis